Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Next Previous
X
Search
Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vesatolimod (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Biomarker
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 22 Feb 2023 Results assessing VES exposure in relation to pharmacodynamic (PD) biomarkers and TTHR, as well as the associations among VES pharmacokinetics (PK)/PD, PD biomarkers and TTHR presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
    • 02 Aug 2022 Results of an exploratory analysis assessing plasma metabolite and lipid profiles in ART-suppressed viremic patients presented at the 24th International AIDS Conference
    • 21 Jul 2021 Results presented at the 11th International AIDS Society Conference on HIV Science

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top